ArticleJournal of translational medicine2026
Application of cerium dioxide nanoparticles in the treatment of intervertebral disc degeneration induced by oxidative stress.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundOxidative stress (OS) induced by local reactive oxygen species (ROS) accumulation plays a vital role in initiating and accelerating intervertebral disc degeneration (IDD). Cerium oxide nanoparticles (CeNPs) have specific and efficient superoxide dismutase (SOD)-mimicking activity for ROS degradation. Their nanoscale particle size and nonstringent catalytic reaction conditions can potentially address challenges faced by traditional antioxidants in terms of remaining stable when used in degenerative avascular intervertebral disc (IVD).
methodsWe cocultured three kinds of IVD cells (cells of annulus fibrosus (AF), cartilage endplate (CEP) and nucleus pulposus (NP)) with CeNPs to determine the safe range of CeNPs concentrations. Additionally, Cell Counting Kit-8 (CCK-8) assay, ROS level assay and calcein/PI staining were performed to detect the protective effect of CeNPs on IVD cells against OS in vitro. Transmission electron microscopy (TEM), inductively coupled plasma mass spectrometry (ICP-MS) and blood analysis were used to describe its distribution pattern and the possible effects CeNPs may have on the body. Histological and immunohistochemical studies were implemented to analyse the capacity of CeNPs to prevent IDD induced by OS. Then western blotting was used to explore the corresponding mechanisms.
resultsThe results showed that ≤ 40 µM CeNPs was safe for the three kinds of IVD cells. CeNPs alleviated the inhibition of cell proliferation and reduced the degree of cell death caused by OS to different degrees. Additionally, the OS-induced degeneration of each part of the IVD was partially relieved after pretreatment with CeNPs. These improvements might be achieved through reducing OS-mediated cellular inflammatory response, extracellular matrix (ECM) catabolism and apoptosis.
conclusionThis study proposes that the local application of CeNPs to the IVD could mitigate OS-induced IDD. Our findings indicate that experimental designs incorporating multiple IVD structures, IVD cells, and surrounding tissues are essential for evaluating drug effect and safety in IDD therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.